

Evonik announces price increase for amino acids used in pharmaceutical and human nutrition applications

November 13, 2018

Evonik Nutrition & Care GmbH will implement a price increase of 8 percent for its amino acid product portfolio for all applications sold via the Health Care Business Line. The price increase will take effect on December 15, 2018.

The price adjustment reflects increasing market requirements, with Evonik having made significant investments to further enhance product quality, supply security and services.

Press Contact

Dr. Jürgen Krauter

Head of Communications
Nutrition & Care
Phone +49 6181 59 -6847
juergen.krauter@evonik.com

Specialist Press Contact

Stephen Allan

External Communication
Health Care
Phone + 49 6151 18-3508
Fax +49 6151 1884-4019
stephen.allan@evonik.com

About Evonik

Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-orientated innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik's corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world with more than 36,000 employees. In fiscal 2017, the enterprise generated sales of €14.4 billion and an operating profit (adjusted EBITDA) of €2.36 billion.

About Nutrition & Care

The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 8,250 employees, and generated sales of around €4.5 billion in 2017.

Evonik Nutrition & Care GmbH

Rellinghauser Straße 1-11
45128 Essen
Telefon +49 201 177-01
Fax +49 201 177-3475
Germany
www.evonik.com

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.

Supervisory Board

Dr. Harald Schwager, Chairman

Managing Directors

Dr. Reiner Beste, Chairman
Dr. Hans Josef Ritzert
Michael Gattermann
Markus Schäfer

Registered office Essen
Registered court
Essen local court
Commercial registry B 25784
HR no. FN 431387 v